查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1993913

癌症生技藥品市場：按藥物、應用、作用機制、最終用戶、國家和地區分類－全球產業分析、市場規模、市場佔有率和預測（2026-2033 年）

Cancer Biologics Market, By Drug, By Application, By Mechanism, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
出版日期: | 出版商: AnalystView Market Insights | 英文 382 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2025年癌症生技藥品市場價值526.1068億美元，預計從2026年到2033年將以8.71%的複合年成長率成長。

癌症生技藥品是一類創新藥物，由蛋白質、抗體和細胞等天然物質製成，旨在預防、治療或控制癌症。與影響體內正常細胞和癌細胞的傳統治療方法不同，癌症生物製劑針對特定的癌細胞。代表性藥物包括單株抗體、癌症疫苗和重組蛋白。它們的作用機轉包括活化人體免疫系統、阻斷腫瘤生長訊號或直接攻擊癌細胞。與傳統治療方法相比，癌症生技藥品通常具有副作用較少的治療優勢。

大約五分之一的人一生中會罹患癌症，隨著人口成長和老化，預計未來幾年全球新患者數將持續增加。在全球醫療保健領域，癌症負擔持續顯著加重，推動了對先進治療方案的需求，而癌症治療市場正是在此背景下蓬勃發展的。根據世界衛生組織及其下屬癌症研究機構－國際癌症研究機構（IARC）統計，2022年全球報告新增癌症病例約2000萬例，癌症相關死亡病例約970萬例，凸顯了癌症對全球健康的重大威脅。因此，各國政府和公共衛生機構正在引進包括生物製藥在內的創新治療方法，作為更廣泛的癌症防治策略的一部分，以提高治療的精準性和臨床療效。

癌症生技藥品市場—市場動態

核准並投入臨床應用的生物製藥療法數量增加

主要醫療市場的監管機構正陸續核准生物製藥療法，加速其融入現代癌症治療通訊協定。隨著法律規範的完善，患者能夠及時獲得先進藥物，醫療服務提供者也擴大將生物製藥納入癌症治療。例如，根據美國食品藥物管理局（FDA）的數據顯示，其藥物評估與研究中心在2023年核准了55種新藥，腫瘤學仍然是生物製藥和標靶治療最活躍的治療領域之一。在此趨勢下，默克和百時美施貴寶等製藥公司正穩步拓展其在腫瘤領域的生物製藥研發管線，包括Keytruda和Opdivo等免疫療法，這顯示醫學界對生物製藥癌症治療的接受度日益提高。總而言之，生物製藥製劑監管核准數量的增加和臨床應用的不斷拓展正在推動癌症治療的進步，改善患者獲得創新療法的機會，並刺激對先進癌症療法研發的持續投資。

癌症生技藥品市場－市場區隔分析：

全球癌症生技藥品市場按藥物、應用、作用機制、最終用戶和地區進行細分。

在三種作用機制中，標靶免疫調節預計將在市場中發揮核心作用。這主要是由於免疫療法的應用日益廣泛，這類療法能夠增強人體免疫系統，使其更有效地識別和攻擊癌細胞。免疫查核點抑制劑等治療方法已在多種癌症類型中展現出顯著的臨床療效，包括肺癌、惡性黑色素瘤和腎癌。政府和監管數據表明，基於免疫系統的生物製藥的作用正在擴大。根據一項國際監管調查，主要市場已核准超過80種免疫查核點抑制劑的臨床適應症，涵蓋約20種癌症類型，其中許多被核准為第一線療法或聯合治療。此外，根據癌症研究所（CRI）發布的一項分析，2011年至2024年間，全球已核准超過120種免疫療法，其中免疫查核點抑制劑佔已核准癌症免疫療法的最大佔有率。因此，標靶免疫調節療法因其能夠為多種癌症帶來持續療效並提高存活率，在臨床實踐中仍備受重視。

從藥物類型來看，單株抗體預計將在癌症生技藥品市場中顯著成長。這類藥物廣泛應用於腫瘤治療領域，因為它們能夠精準靶向癌細胞上的特定蛋白，從而在增強治療效果的同時，最大限度地減少對健康組織的損傷。這些生技藥品廣泛應用於多種癌症類型，包括乳癌、肺癌和大腸癌，這推動了其在全球的臨床應用不斷擴大。 2024年FDA生物製藥核准情況的分析顯示，共有13種單株抗體獲得監管部門核准，其中包括一些用於腫瘤治療的藥物，反映了抗體類生物製藥的持續創新和監管重點。例如，默克的免疫療法藥物Keytruda預計在2024年將創造約294.8億美元的全球整體銷售額，使其成為全球領先的抗癌生物製藥之一。

癌症生技藥品市場—區域洞察

從區域來看，癌症生技藥品市場在醫療基礎設施、研究能力和治療方法可近性方面存在顯著的區域差異。北美地區憑藉其先進的醫療基礎設施、政府大力支持的研究項目以及完善的主導法規環境（有利於創新生物癌症治療方法的開發和核准），預計將繼續保持其在癌症生技藥品市場的領先地位。此外，該地區許多大型生物技術和製藥公司的存在，以及廣泛的臨床研究活動，持續推動生物製藥製劑在癌症治療領域的應用。一些政府數據進一步凸顯了該地區對癌症治療的強勁臨床需求。根據美國癌症協會統計，2022年全球整體新增癌症病例約2000萬例，死亡病例約970萬例，凸顯了全球癌症負擔的日益加重以及對生物製劑等先進治療方法的迫切需求。

在北美，美國憑藉其龐大的患者群體和強大的生物醫學研究生態系統，成為區域市場的主要貢獻者。根據美國疾病管制與預防中心（CDC）的美國癌症統計項目，2022年美國報告了1,851,238例新增癌症病例，預計2023年將有613,349例癌症相關死亡病例，這清楚地表明了對先進癌症治療方案的巨大需求。總體而言，嚴重的癌症負擔、政府的支持、先進的醫療保健體係以及強大的研發投入正在推動癌症生技藥品市場的發展。

印度癌症生技藥品市場—各國概況

在癌症負擔日益加重、醫療基礎設施不斷完善以及對生物技術創新的日益重視的推動下，印度正逐步崛起為癌症生技藥品的重要市場。根據印度醫學研究理事會（ICMR）國家癌症登記計畫（NCRP）的數據，2022年印度報告了約146萬例新增癌症病例，預計到2025年這一數字將達到約157萬例。這表明對生物製藥療法等先進治療方法的需求日益成長。多項政府措施也正在加強該國的癌症診療水準。例如，印度衛生和家庭福利部正在實施國家癌症、糖尿病、心血管疾病和中風預防與管理計劃（NPCDCS），該計劃致力於改善各邦的癌症篩檢、診斷和治療基礎設施。日益加重的癌症負擔、政府的醫療支持以及本土生物製藥公司不斷湧入市場，這些因素共同作用，正在鞏固印度在癌症生技藥品領域的地位。對生物技術研發的持續投入和生物相似藥生產的擴大有望改善獲得先進癌症治療的機會，並促進該國生物製藥市場的逐步發展。

目錄

第1章：生技藥品市場概述

  • 分析範圍
  • 市場估算期

第2章執行摘要

  • 市場區隔
  • 競爭考察

第3章：生技藥品市場的主要趨勢

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 未來市場趨勢

第4章：生技藥品產業分析

  • PEST分析
  • 波特五力分析
  • 市場成長前景展望圖
  • 管理體制分析

第5章：生技藥品市場：地緣政治緊張局勢加劇的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：生技藥品市場趨勢

  • 癌症生技藥品市場佔有率分析，2025年
  • 主要製造商的細分數據
    • 對現有公司的分析
    • 新興企業分析

第7章 癌症生技藥品市場：依藥物類型分類

  • 概述
    • 細分市場佔有率分析：依藥物分類
    • 單株抗體
    • 細胞療法
    • 重組蛋白和細胞激素
    • 癌症疫苗
    • 溶瘤病毒

第8章 癌症生技藥品市場：依應用領域分類

  • 概述
    • 細分市場佔有率分析：按應用
    • 血癌
    • 乳癌
    • 肺癌
    • 大腸直腸癌和其他固體癌

第9章：癌症生技藥品市場：依作用機制分類

  • 概述
    • 細分市場佔有率分析：依作用機制分類
    • 標靶免疫調節
    • 腫瘤特異性細胞療法
    • 血管生成和生長因子抑制劑
    • 其他

第10章 癌症生技藥品市場：依最終用戶分類

  • 概述
    • 細分市場佔有率分析：依最終用戶分類
    • 醫院
    • 診所
    • 研究機構
    • 其他

第11章生技藥品市場：依地區分類

  • 介紹
  • 北美洲
    • 概述
    • 主要製造商：北美
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 主要製造商：歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 概述
    • 主要製造商：亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 其他亞太國家
  • 拉丁美洲
    • 概述
    • 主要製造商：拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他拉丁美洲國家
  • 中東和非洲
    • 概述
    • 主要生產商：中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 其他中東和非洲國家

第12章：主要供應商分析：癌症生技藥品產業

  • 競爭基準
    • 競爭對手儀錶板
    • 競爭定位
  • 公司簡介
    • F. Hoffmann La Roche Ltd
    • Novartis AG
    • Merck & Co.
    • Bristol Myers Squibb
    • Johnson & Johnson
    • Eli Lilly and Company
    • Sanofi
    • AbbVie Inc.
    • Amgen Inc.
    • BioNTech
    • Genmab
    • Incyte Corporation
    • Roche
    • Bayer
    • Others

第13章：分析師的綜合視角

簡介目錄
Product Code: ANV6124

Cancer Biologics Market size was valued at US$ 52,610.68 Million in 2025, expanding at a CAGR of 8.71% from 2026 to 2033.

Cancer biologics are an innovative class of medicines derived from living organisms such as proteins, antibodies, or cells, designed to prevent, treat, or manage cancer. They target specific cancer cells, unlike the traditional way, which affects both healthy and cancerous cells in the body. Common drug types include monoclonal antibodies, cancer vaccines, recombinant proteins, and many more. They work by adapting the immune system in the body, blocking tumor growth signals, or directly attacking cancer cells. Cancer biologics often offer care treatment with potentially fewer side effects compared to conventional therapies.

About 1 in 5 people develop cancer in their lifetime, and global incidence is anticipated to increase new cases in the coming years due to population growth and ageing. This market is evolving within a global healthcare environment characterized by a significant and rising burden of cancer, which continues to drive the demand for advanced therapeutic solutions. According to the WHO and its cancer research agency, the International Agency for Research on Cancer, there were about 20 million newly diagnosed cancer cases and approximately 9.7 million cancer-related deaths worldwide in 2022, highlighting the substantial global health challenge posed by the disease. Therefore, governments and public health institutions are listing innovative therapeutic modalities, including biologics, to improve treatment accuracy and improve clinical outcomes as part of broader cancer control strategies.

Cancer Biologics Market- Market Dynamics

Increasing Regulatory Approvals and Clinical Adoption of Biologic Therapies

Governing authorities across major healthcare markets are progressively approving biologic therapies, encouraging their integration into contemporary cancer treatment protocols. As regulatory frameworks facilitate timely access to advanced medicines, healthcare providers are increasingly integrating biologic treatments into cancer care. For instance, according to the U.S. Food and Drug Administration (FDA), the Center for Drug Evaluation and Research approved 55 novel drugs in 2023, with oncology remaining one of the most active therapeutic areas for biologic and targeted therapies. Amid these developments, pharmaceutical companies such as Merck & Co. and Bristol Myers Squibb are steadily broadening their biologic oncology pipelines, including immunotherapy medicines such as Keytruda and Opdivo, highlighting increasing medical acceptance of biologic-based cancer therapies. Overall, the growing number of regulatory approvals and expanding clinical use of biologic treatments are fostering progress in oncology care, improving patient access to innovative therapies, and encouraging sustained investment in advanced cancer treatment development.

Cancer Biologics Market- Segmentation Analysis:

The Global Cancer Biologics Market is segmented on the basis of Drug, Application, Mechanism, End User, and Region.

Among the three categories of mechanism, targeted immune modulation is anticipated to play a central role in the market. This is largely due to the increasing adoption of immunotherapy approaches that enhance the body's immune system to recognize and attack cancer cells more effectively. Therapies such as immune checkpoint inhibitors have demonstrated significant clinical benefits across several cancer types, including lung cancer, melanoma, and renal cancer. Government and regulatory data illustrate the growing role of immune-based biologics. A cross-national regulatory study reported that more than 80 clinical indications for immune checkpoint inhibitors have been approved across major markets, covering around 20 different cancer types, with many approvals granted as first-line or combination therapies. In addition, insights published by the Cancer Research Institute (CRI) show that over 120 immunotherapy approvals have been granted globally between 2011 and 2024, with immune checkpoint inhibitors representing the largest share of approved cancer immunotherapies. As a result, targeted immune modulation continues to gain strong clinical acceptance due to its ability to deliver durable responses and improved survival outcomes in several cancers.

On the basis of the drug, monoclonal antibodies are forecasted to register meaningful growth in the cancer biologics market. These drugs are broadly used in oncology because they can precisely target specific proteins on cancer cells, thus enhancing treatment effectiveness while reducing damage to healthy tissues. These biologic drugs are widely applied across several cancer types, including breast cancer, lung cancer, and colorectal cancer, which has supported their growing clinical adoption worldwide. Analysis of FDA biologic approvals in 2024 indicates that 13 monoclonal antibodies received regulatory authorization, including several indicated for oncology, reflecting the continued innovation and regulatory focus on antibody-based biologic medicines. For example, the immunotherapy Keytruda, developed by Merck & Co., generated approximately $29.48 billion in global sales in 2024, making it one of the world's leading oncology biologic medicines.

Cancer Biologics Market- Geographical Insights

Geographically, the cancer biologics market reflects significant regional differences in healthcare infrastructure, research capabilities, and treatment adoption. North America is expected to maintain prominence in the cancer biologics market because, it benefits from advanced healthcare infrastructure, strong government-supported research programs, and a well-established regulatory environment that facilitates the development and approval of innovative biologic cancer therapies. In addition, the occurrence of major biotechnology and pharmaceutical companies, along with extensive clinical research activities, continues to support the regional adoption of biologic-based oncology treatments. Some government data further highlight the strong clinical demand for cancer therapies within the region. According to the American Cancer Society, approximately 20 million new cancer cases and 9.7 million deaths were reported globally in 2022, emphasizing the growing global burden of cancer and the need for advanced treatments such as biologics.

Within North America, the United States represents a major contributor to the regional market due to its large patient population and strong biomedical research ecosystem. According to the Centers for Disease Control and Prevention (CDC) through the United States Cancer Statistics program, 1,851,238 new cancer cases were reported in the United States in 2022, and 613,349 cancer-related deaths occurred in 2023, illustrating the substantial need for advanced cancer treatment solutions. Overall, the combination of a significant cancer burden, supportive government initiatives, advanced healthcare systems, and strong research investments positions the cancer biologics market.

India Cancer Biologics Market- Country Insights

India is gradually emerging as an important market for cancer biologics due to the rising cancer burden, expanding healthcare infrastructure, and increasing focus on biotechnology innovation. According to the Indian Council of Medical Research (ICMR) through the National Cancer Registry Programme (NCRP), India reported approximately 1.46 million new cancer cases in 2022, and the incidence is projected to reach around 1.57 million cases by 2025, highlighting the growing need for advanced treatment options such as biologic therapies. Some government initiatives are also strengthening oncology care in the country. For instance, the Ministry of Health and Family Welfare, Government of India, implements the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS), which focuses on improving cancer screening, diagnosis, and treatment infrastructure across states. Together, the growing cancer burden, supportive government healthcare initiatives, and increasing participation of domestic biopharmaceutical companies are collectively strengthening India's role in the cancer biologics landscape. Continued investments in biotechnology research and the expansion of biosimilar production are expected to improve accessibility to advanced cancer therapies and support the gradual development of the country's biologics market.

Cancer Biologics Market- Competitive Landscape:

Cancer Biologics market is highly competitive and innovation driven, categorized by strategic alliances, M&A activity, and robust R&D. The market validates a competitive environment supported by the presence of several global pharmaceutical and biotechnology companies engaged in the development of advanced biologic therapies for oncology. Market participants are prioritizing research and innovation to introduce targeted treatments such as monoclonal antibodies, immune checkpoint inhibitors, and cell-based therapies that aim to improve clinical outcomes for cancer patients. Prominent organizations, including F. Hoffmann-La Roche Ltd, Merck & Co., Amgen Inc., and other maintain notable positions in the market due to their extensive oncology pipelines and continued focus on biologic innovation. In addition, companies such as AstraZeneca, Pfizer Inc., and many more are actively strengthening their immuno-oncology and biologics research capabilities. Collectively, these companies contribute to a dynamic and innovation-oriented competitive landscape, where continuous product development and collaborative research efforts support the advancement of modern cancer treatment approaches.

Recent Developments:

In February 2026, Innovent Biologics and Eli Lilly partnered to jointly develop oncology and immunology therapies, with Innovent leading early-stage development in China and Lilly managing global commercialization outside Greater China. This collaboration enhances the global cancer biologics pipeline, combining regional expertise and international reach to expand patient access to innovative cancer treatments.

In June 2025, Alvotech and Dr. Reddy's Laboratories partnered to co-develop, manufacture, and commercialize a pembrolizumab biosimilar. By combining Alvotech's R&D and manufacturing expertise with Dr. Reddy's global commercialization network, the collaboration aims to enhance worldwide accessibility to this leading cancer immunotherapy, supporting broader patient access and affordability.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CANCER BIOLOGICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • F. Hoffmann La Roche Ltd
  • Novartis AG
  • Merck & Co.
  • Bristol Myers Squibb
  • Johnson & Johnson
  • Eli Lilly and Company
  • Sanofi
  • AbbVie Inc.
  • Amgen Inc.
  • BioNTech
  • Genmab
  • Incyte Corporation
  • Roche
  • Bayer
  • Others

GLOBAL CANCER BIOLOGICS MARKET, BY DRUG- MARKET ANALYSIS, 2020 - 2033

  • Monoclonal antibodies
  • Cell Therapies
  • Recombinant proteins & cytokines
  • Cancer Vaccines
  • Oncolytic viruses

GLOBAL CANCER BIOLOGICS MARKET, BY APPLICATION- MARKET ANALYSIS, 2020 - 2033

  • Hematologic cancers
  • Breast Cancer
  • Lung Cancer
  • Colorectal and other solid tumors

GLOBAL CANCER BIOLOGICS MARKET, BY MECHANISM- MARKET ANALYSIS, 2020 - 2033

  • Targeted immune modulation
  • Tumor specific cell based therapies
  • Angiogenesis and growth factor inhibitors
  • Others

GLOBAL CANCER BIOLOGICS MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033

  • Hospitals
  • Clinics
  • Research Institutes
  • Others

GLOBAL CANCER BIOLOGICS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Cancer Biologics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Cancer Biologics Market Snippet by Drug
    • 2.1.2. Cancer Biologics Market Snippet by Application
    • 2.1.3. Cancer Biologics Market Snippet by Mechanism
    • 2.1.4. Cancer Biologics Market Snippet by End User
    • 2.1.5. Cancer Biologics Market Snippet by Country
    • 2.1.6. Cancer Biologics Market Snippet by Region
  • 2.2. Competitive Insights

3. Cancer Biologics Key Market Trends

  • 3.1. Cancer Biologics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Cancer Biologics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Cancer Biologics Market Opportunities
  • 3.4. Cancer Biologics Market Future Trends

4. Cancer Biologics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Cancer Biologics Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Cancer Biologics Market Landscape

  • 6.1. Cancer Biologics Market Share Analysis, 2025
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Cancer Biologics Market - By Drug

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug, 2025 & 2033 (%)
    • 7.1.2. Monoclonal antibodies
    • 7.1.3. Cell Therapies
    • 7.1.4. Recombinant proteins & cytokines
    • 7.1.5. Cancer Vaccines
    • 7.1.6. Oncolytic viruses

8. Cancer Biologics Market - By Application

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Application, 2025 & 2033 (%)
    • 8.1.2. Hematologic cancers
    • 8.1.3. Breast Cancer
    • 8.1.4. Lung Cancer
    • 8.1.5. Colorectal and other solid tumors

9. Cancer Biologics Market - By Mechanism

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Mechanism, 2025 & 2033 (%)
    • 9.1.2. Targeted immune modulation
    • 9.1.3. Tumor specific cell based therapies
    • 9.1.4. Angiogenesis and growth factor inhibitors
    • 9.1.5. Others

10. Cancer Biologics Market - By End User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Application, 2025 & 2033 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Clinics
    • 10.1.4. Research Institutes
    • 10.1.5. Others

11. Cancer Biologics Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Cancer Biologics Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Cancer Biologics Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Cancer Biologics Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Cancer Biologics Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Cancer Biologics Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)

12. Key Vendor Analysis- Cancer Biologics Industry

  • 12.1. Competitive Benchmarking
    • 12.1.1. Competitive Dashboard
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. F. Hoffmann La Roche Ltd
    • 12.2.2. Novartis AG
    • 12.2.3. Merck & Co.
    • 12.2.4. Bristol Myers Squibb
    • 12.2.5. Johnson & Johnson
    • 12.2.6. Eli Lilly and Company
    • 12.2.7. Sanofi
    • 12.2.8. AbbVie Inc.
    • 12.2.9. Amgen Inc.
    • 12.2.10. BioNTech
    • 12.2.11. Genmab
    • 12.2.12. Incyte Corporation
    • 12.2.13. Roche
    • 12.2.14. Bayer
    • 12.2.15. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us